

## IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

6 November 2020

### STATEMENT PURSUANT TO LISTING RULE 4.7C.3

**MELBOURNE** — Imagion Biosystems Limited (ASX: **IBX**) (the **Company**), advises that in accordance with Listing Rule 4.7C.3, and as noted in the Item 6 of the Appendix 4C Cashflow Statement lodged by the Company with the Australian Securities Exchange (ASX) on 27 October 2020, payments to related parties and their associates during the quarter ended 30 September 2020 were \$115k. These payments related to Directors fees and executive salaries.

### ENDS

#### About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit [www.imagionbiosystems.com](http://www.imagionbiosystems.com)

#### Authorisation & Additional information

This announcement was authorised by the Board of Directors of Imagion Biosystems Limited

#### U.S. Media Contact:

Matthew Wygant  
[matthew@biotechwriting.com](mailto:matthew@biotechwriting.com)  
+1-408-905-7630

#### Australian Media & Investor Relations:

Kyahn Williamson, WE Communications  
[We-AUImagionBiosystems@we-worldwide.com](mailto:We-AUImagionBiosystems@we-worldwide.com)  
+61 (0) 401018828